Portola Pharmaceuticals Inc (NASDAQ:PTLA) – Analysts at William Blair dropped their Q4 2019 earnings per share estimates for Portola Pharmaceuticals in a research note issued to investors on Tuesday. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $0.28 for the quarter, down from their prior estimate of $0.29. William Blair has a “Buy” rating on the stock. William Blair also issued estimates for Portola Pharmaceuticals’ FY2021 earnings at $6.63 EPS.
Several other research analysts have also recently issued reports on the company. Oppenheimer set a $80.00 price objective on Portola Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 15th. Goldman Sachs Group initiated coverage on Portola Pharmaceuticals in a research report on Friday, December 1st. They set a “buy” rating and a $75.00 price objective for the company. BidaskClub cut Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. Zacks Investment Research cut Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, February 13th. Finally, Citigroup reaffirmed a “buy” rating and set a $74.00 price objective on shares of Portola Pharmaceuticals in a research report on Thursday, December 28th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $64.40.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.46) by $0.05. The business had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $3.71 million. Portola Pharmaceuticals had a negative return on equity of 108.43% and a negative net margin of 1,268.34%. The business’s quarterly revenue was down 28.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.95) EPS.
Institutional investors have recently bought and sold shares of the company. Oppenheimer Asset Management Inc. lifted its holdings in shares of Portola Pharmaceuticals by 251.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 2,047 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Portola Pharmaceuticals by 54.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 1,141 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in Portola Pharmaceuticals during the 3rd quarter valued at approximately $178,000. Sei Investments Co. purchased a new stake in Portola Pharmaceuticals during the 3rd quarter valued at approximately $217,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Portola Pharmaceuticals during the 3rd quarter valued at approximately $218,000. 88.43% of the stock is owned by institutional investors and hedge funds.
In other news, Director Henry Ward Wolff sold 12,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $47.00, for a total value of $564,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: “Portola Pharmaceuticals Inc (PTLA) to Post Q4 2019 Earnings of $0.28 Per Share, William Blair Forecasts” was published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/03/14/portola-pharmaceuticals-inc-ptla-to-post-q4-2019-earnings-of-0-28-per-share-william-blair-forecasts.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.